BTAI insider filings

BioXcel Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen BTAI transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for BTAI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — BioXcel Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-08-144Atkins Susan E. — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-06-174Rodriguez Javier — See RemarksOption exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-06-174Yocca Frank — Chief Scientific OfficerOption exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-06-174Mehta Vimal — CEO and President, DirectorOption exercise (M): 219 · Option exercise (M): 219 (derivative) @ $0EDGAR
2026-06-174Steinhart Richard I — Chief Financial OfficerOption exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-05-224Yocca Frank — Chief Scientific OfficerOption exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0EDGAR
2026-05-224Rodriguez Javier — See RemarksOption exercise (M): 17,500 · Sale (S): 6,560 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0EDGAR
2026-05-224Mehta Vimal — CEO and President, DirectorOption exercise (M): 49,758 · Sale (S): 19,419 @ $1.09 · Option exercise (M): 49,758 (derivative) @ $0EDGAR
2026-05-224Steinhart Richard I — Chief Financial OfficerOption exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0EDGAR
2026-05-074Mehta Vimal — CEO and President, DirectorOption exercise (M): 18,000 · Option exercise (M): 18,000 (derivative) @ $0EDGAR
2026-05-074Yocca Frank — Chief Scientific OfficerOption exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0EDGAR
2026-05-074Rodriguez Javier — See RemarksOption exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0EDGAR
2026-05-074Steinhart Richard I — Chief Financial OfficerOption exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0EDGAR
2026-03-164Mehta Vimal — CEO and President, DirectorOption exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0EDGAR
2026-03-164Rodriguez Javier — See RemarksOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-03-164Yocca Frank — Chief Scientific OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-03-164Steinhart Richard I — Chief Financial OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-01-124Laumas Sandeep — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-124Bray June — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-124MACK DAVID J. — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-124Votruba Michal — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-124Patni Rajiv — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-124MUELLER PETER — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-124MILLER MICHAEL PATRICK — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2026-01-054Yocca Frank — Chief Scientific OfficerGrant/award (A): 70,000 (derivative) @ $0EDGAR
2026-01-054Mehta Vimal — CEO and President, DirectorGrant/award (A): 199,032 (derivative) @ $0EDGAR
2026-01-054Rodriguez Javier — See RemarksGrant/award (A): 70,000 (derivative) @ $0EDGAR
2026-01-054Steinhart Richard I — Chief Financial OfficerGrant/award (A): 70,000 (derivative) @ $0EDGAR
2025-12-154Mehta Vimal — CEO and President, DirectorOption exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0EDGAR
2025-12-154Rodriguez Javier — See RemarksOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-12-154Yocca Frank — Chief Scientific OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-12-154Steinhart Richard I — Chief Financial OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-11-034MACK DAVID J. — DirectorOption exercise (M): 1,694 · Option exercise (M): 1,694 (derivative) @ $0EDGAR
2025-10-014MACK DAVID J. — DirectorOption exercise (M): 1,694 · Option exercise (M): 1,694 (derivative) @ $0EDGAR
2025-09-164Mehta Vimal — CEO and President, DirectorOption exercise (M): 163 · Option exercise (M): 219 · Option exercise (M): 163 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0EDGAR
2025-09-164Rodriguez Javier — See RemarksOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-09-164Yocca Frank — Chief Scientific OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-09-164Steinhart Richard I — Chief Financial OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-09-024MACK DAVID J. — DirectorOption exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0EDGAR
2025-08-054Rodriguez Javier — See RemarksGrant/award (A): 9,000 (derivative) @ $0EDGAR
2025-08-054Yocca Frank — Chief Scientific OfficerGrant/award (A): 9,000 (derivative) @ $0EDGAR
2025-08-054Mehta Vimal — CEO and President, DirectorGrant/award (A): 18,000 (derivative) @ $0EDGAR
2025-08-054Steinhart Richard I — Chief Financial OfficerGrant/award (A): 9,000 (derivative) @ $0EDGAR
2025-07-314MACK DAVID J. — DirectorOption exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0EDGAR
2025-07-224Mehta Vimal — CEO and President, DirectorGrant/award (A): 15,625EDGAR
2025-07-224Yocca Frank — Chief Scientific OfficerGrant/award (A): 4,375EDGAR
2025-07-224Rodriguez Javier — See RemarksGrant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0EDGAR
2025-07-224Steinhart Richard I — Chief Financial OfficerGrant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0EDGAR
2025-06-304MACK DAVID J. — DirectorOption exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0EDGAR
2025-06-164Steinhart Richard I — Chief Financial OfficerOption exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR

Recent 8-K events — BioXcel Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-10-308-K2.01 — Completion of Acquisition or Disposition of Assets
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-018-K2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
EDGAR
2026-08-288-K1.01 — Entry into a Material Definitive Agreement
1.03 — Bankruptcy or Receivership
EDGAR
2026-08-258-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-248-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-118-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-038-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-068-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-158-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-178-K3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BTAI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs